A Double-Blind, Placebo-Controlled Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVP-6124 in Participants With Schizophrenia on Stable Monotherapy With Selected Antipsychotics.
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2014
At a glance
- Drugs Encenicline (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors EnVivo Pharmaceuticals; FORUM Pharmaceuticals
- 16 Mar 2012 Actual patient number changed from 20 to 21 as reported by ClinicalTrials.gov.
- 16 Mar 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01556763).
- 16 Mar 2012 Primary endpoints identified as reported by ClinicalTrials.gov.